Integrating BCMA-directed bispecific antibodies into the treatment paradigm for MM
During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss the integration of B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs) into the treatment paradigm for multiple myeloma. The discussion was led by Miles Prince (Peter MacCallum Cancer Centre, Melbourne, AU) and explored key considerations for patient selection, treatment sequencing, and implementation of BsAb therapy in clinical practice.
Prince reviews the currently approved BCMA-directed BsAbs and key factors influencing treatment selection, including disease…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.